NIP

New Innovative Products (NIP)

ZIM Laboratories continues to spearhead innovation with its New Innovative Products (NIP), comprising complex and advanced generic pharmaceuticals developed in-house. Leveraging proprietary technologies and non-infringing manufacturing processes, these NIP target a market size of $500 million to $1.5 billion (excluding the USA and Japan).
As next-generation molecules, several of these NIP have the potential to become the first or second generics in select markets.

innovation

Progress and Global Expansion of New Innovative Products (NIP)

Our Technology

Our NIP have demonstrated strong demand in Pharmerging and Rest of World (RoW) markets, and we are continuing filings in these regions to capitalize on further opportunities for commercializing these innovative products.

Technology

Currently, we have 10 NIP in various stages of dossier completion and registration. The development of these 10 NIP is nearing completion, with an additional 6-8 NIP in progress. We have 4-6 filings planned in the EU for FY25, with several of these products also slated for filing in Australia, Brazil, Mexico, and South Africa.

Technology

To date, we have filed a total of 6 New Innovative Products (NIP) in the EU and have successfully received Marketing Authorization for one of these products.

R & D Expense

innovation

R&D Team

Our R&D Team is led by a highly experienced leader in pharmaceutical development and supported by a professionally qualified team.

76
Post Graduates
2
PHDs
85
R&D Team Size
technology

4 NIP Proprietary & Non - Infringing Technology Platforms.

1. MICRO EMULSION COATING (MECT)
Micro-Emulsion Coating Technology (MECT) is used for the solubilization of oil-soluble drugs and liquids in the oil phase, followed by micro-emulsification with an aqueous phase containing a polymer to coat the substrate.

2. PELLET COLD FORMING (PCFT)
Pellet Cold Forming Technology (PCFT) is used for heat-sensitive materials that either lose potency or transform into another form when processed at normal temperatures.

3. RAPID GELATION DRUG RELEASE (RGDRT)
Rapid Gelation Drug Release Technology (RGDRT) is used to release drugs with pseudo-zero-order kinetics and serves as an alternative to OROS® technology.

4. MATRIX PORE FORMING (MAPOTAB)
Matrix Pore Forming Tablet Technology (MAPOTAB) is applied for drug release through pores into aqueous media.